List of Excipients in Branded Drug CAMZYOS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Myokardia Inc	CAMZYOS	mavacamten	73625-111	CROSCARMELLOSE SODIUM	2036-04-28
Myokardia Inc	CAMZYOS	mavacamten	73625-111	FERRIC OXIDE RED	2036-04-28
Myokardia Inc	CAMZYOS	mavacamten	73625-111	FERRIC OXIDE YELLOW	2036-04-28
Myokardia Inc	CAMZYOS	mavacamten	73625-111	FERROSOFERRIC OXIDE	2036-04-28
Myokardia Inc	CAMZYOS	mavacamten	73625-111	GELATIN	2036-04-28
Myokardia Inc	CAMZYOS	mavacamten	73625-111	HYPROMELLOSE	2036-04-28

CAMZYOS Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

CAMZYOS, Bristol Myers Squibb's brand for mavacamten, uses a conventional immediate-release hard-gelatin capsule formulation. The commercial opportunity is not based on a novel excipient platform. It is concentrated in reliable supply of pharmaceutical-grade excipients, capsule-shell components, alternate-source qualification, dose-strength manufacturing, stability control, and generic formulation development constrained by CAMZYOS's regulatory and patent position.

CAMZYOS was approved by the U.S. Food and Drug Administration in April 2022 for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.[1] The product is subject to the CAMZYOS Risk Evaluation and Mitigation Strategy, or REMS, because mavacamten can reduce left ventricular ejection fraction and cause heart failure.[2]

What excipients are used in CAMZYOS capsules?

The core CAMZYOS capsule formulation uses common solid-oral excipients:

Component	Function in the formulation	Commercial relevance
Lactose monohydrate	Diluent and capsule-fill carrier	High-volume commodity with supplier qualification and supply-chain value
Microcrystalline cellulose	Diluent, compactability aid, and powder-flow support	Important for blend uniformity and low-dose content uniformity
Croscarmellose sodium	Superdisintegrant	Supports rapid capsule-content dispersion
Colloidal silicon dioxide	Glidant and flow aid	Controls powder flow and reduces fill-weight variability
Magnesium stearate	Lubricant	Requires control of blending time and concentration
Gelatin	Hard-capsule shell material	Supports capsule manufacture and shell-color differentiation
Titanium dioxide and colorants	Capsule-shell opacity and identification	Relevant to strength-specific visual coding and regulatory compliance

The FDA prescribing information identifies the inactive ingredients in the drug product. The exact capsule-shell color system varies by strength and is part of the product's identification architecture.[1]

CAMZYOS is supplied in 2.5 mg, 5 mg, 10 mg, and 15 mg capsules. The low drug load makes excipient selection important. Mavacamten represents a small fraction of total capsule fill, so particle-size distribution, bulk density, segregation behavior, and blending performance affect dose uniformity.

How does the CAMZYOS formulation affect excipient strategy?

The formulation creates four primary technical priorities.

Content uniformity at low drug load

Mavacamten is administered at low milligram strengths. A direct-fill blend must prevent segregation between the active pharmaceutical ingredient and larger-volume excipients. Microcrystalline cellulose and lactose provide the bulk required for capsule filling, while colloidal silicon dioxide can improve flow.

An excipient supplier with tightly controlled particle-size distribution can offer more value than a low-cost commodity supplier. Critical attributes include:

• Particle-size distribution
• Bulk and tapped density
• Moisture content
• Flow rate
• Surface area
• Compressibility and deagglomeration behavior
• Lot-to-lot chemical consistency

Disintegration and dissolution

Croscarmellose sodium supports capsule-content disintegration after the gelatin shell dissolves. Excessive magnesium stearate or over-lubrication can reduce wetting and slow dissolution. The excipient strategy therefore requires a defined blending sequence and controlled lubrication time.

For a generic applicant, matching dissolution across all four strengths is likely to be more important than creating a novel release profile. CAMZYOS is an immediate-release product, so a materially different release mechanism would create unnecessary regulatory and clinical risk.

Stability and moisture control

Gelatin capsules, lactose, croscarmellose sodium, and microcrystalline cellulose can contribute to moisture-related stability behavior. Mavacamten is a potent, low-dose compound, making chemical degradation and blend uniformity more consequential than capsule weight alone.

Commercial opportunities include:

• Low-moisture excipient grades
• High-purity lactose with controlled reducing-sugar specifications
• Low-peroxide or tightly controlled cellulose grades
• Moisture-barrier packaging
• Desiccant-compatible bottle systems
• Stability-indicating analytical packages
• Excipient compatibility screening

Capsule identification

The four CAMZYOS strengths require clear visual differentiation. Capsule-shell suppliers can compete through color consistency, print quality, gelatin performance, defect rates, and global regulatory support. The opportunity is strongest for suppliers capable of supplying multiple strengths under a unified quality system.

What commercial opportunities exist for CAMZYOS excipient suppliers?

The most accessible opportunities are in supply assurance rather than proprietary formulation ownership.

Qualified alternate sources

Bristol Myers Squibb and its contract manufacturing partners must manage continuity for every critical excipient. A supplier that qualifies as a second source for lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, or capsule shells can capture recurring business without owning a drug patent.

The business case is strongest where the supplier offers:

• A comparable or superior compendial grade
• Reliable global production
• Strong change-control procedures
• DMF or regulatory support where applicable
• Low extractables and leachables risk
• Consistent supply during demand growth
• Data supporting formulation comparability

Specialty grades for low-dose capsules

Standard excipients may work for CAMZYOS, but specialty grades can improve process capability. Potentially valuable offerings include:

• Engineered lactose grades with improved flow
• Co-processed microcrystalline cellulose systems
• Low-density excipients for capsule-fill optimization
• Narrow-distribution croscarmellose sodium
• Surface-treated glidants
• Vegetable-based capsule shells
• Low-moisture gelatin systems

The commercial barrier is qualification. A new grade would require formulation, stability, dissolution, manufacturing, and regulatory comparability work. The supplier must show a measurable benefit, such as lower blend segregation, reduced fill-weight variation, improved throughput, or fewer rejected batches.

Contract development and manufacturing

CDMOs with expertise in low-dose capsule products can compete for CAMZYOS-related work through:

• Analytical method development
• Blend uniformity studies
• Capsule-filling process development
• Stability programs
• Scale-up and process validation
• Packaging qualification
• Generic drug development

The REMS requirement raises the value of a CDMO or generic partner with experience in controlled distribution, pharmacy certification, patient enrollment, and prescriber compliance systems.

What patents protect CAMZYOS and its formulation?

CAMZYOS is protected by a combination of compound, therapeutic-use, formulation, and regulatory exclusivity rights. The relevant rights are not limited to excipients.

Protection category	Strategic effect
Mavacamten compound patents	Can block manufacture or sale of the active ingredient
Treatment-method patents	May restrict labeled use in hypertrophic cardiomyopathy
Formulation or dosage-form patents	Can affect capsule composition, strength, or release characteristics
Regulatory exclusivity	Delays certain FDA approval pathways independent of patent validity
REMS obligations	Increase operational barriers for generic commercialization
Manufacturing know-how	Can protect scale-up, impurity control, and process performance

The FDA approved CAMZYOS as a new molecular entity in 2022. Its five-year new chemical entity exclusivity generally runs through April 2027, subject to the applicable regulatory calculation and any pediatric exclusivity.[1] Orange Book patent listings and current expiration dates should be evaluated separately from FDA exclusivity because patent term, patent-term adjustment, patent-term extension, and pediatric exclusivity can produce different endpoints.[3]

Excipients that are already widely used in oral capsules are unlikely to provide meaningful freedom-to-operate protection by themselves. A supplier's defensible position is more likely to come from manufacturing know-how, proprietary particle engineering, co-processed systems, quality data, or contractual qualification status.

When does CAMZYOS lose exclusivity?

CAMZYOS does not have a single exclusivity date.

Regulatory exclusivity

The five-year NCE exclusivity period began with FDA approval in April 2022. It generally prevents submission of an ANDA referencing the product for five years, except that a Paragraph IV certification may be submitted after four years.[1]

That creates an approximate regulatory sequence:

Event	Approximate timing
FDA approval	April 2022
Four-year Paragraph IV submission point	April 2026
Five-year NCE exclusivity endpoint	April 2027
Potential ANDA approval timing	Dependent on patents, litigation, and FDA review
Commercial generic entry	Dependent on patent resolution and approval

Patent protection may extend beyond the NCE period. A generic applicant must address each Orange Book-listed patent through a Paragraph I, II, III, or IV certification. A Paragraph IV challenge can trigger patent litigation and a 30-month stay of approval under the Hatch-Waxman framework.[4]

Patent expiry

The commercial entry date depends on the latest enforceable patent that covers the proposed product or its method of use. A patent that covers only a method of treatment may create a different risk profile from a patent that covers the active compound or a capsule formulation.

Patent-term analysis should therefore distinguish:

1. Compound claims.
2. Pharmaceutical composition claims.
3. Dose-regimen claims.
4. Patient-selection claims.
5. Manufacturing claims.
6. Formulation-specific claims.

A generic company can sometimes avoid a formulation patent by using different excipient grades, a different manufacturing process, or a different capsule-shell composition. That strategy does not avoid compound or method-of-use claims.

Which companies are challenging CAMZYOS?

CAMZYOS is a small-molecule product, so the relevant challengers are generic-drug companies, not biosimilar developers. A biosimilar pathway under section 351(k) does not apply to mavacamten.[5]

Public commercial risk should be assessed through:

• FDA Orange Book patent certifications
• ANDA litigation filings
• Paragraph IV notices
• District-court docket activity
• Inter partes review petitions
• Patent settlements
• FDA approval records

The absence of a publicly identified challenger does not eliminate future risk. The first significant risk window begins when the four-year NCE exclusivity point approaches, because Paragraph IV filings may then be submitted.

What is the FDA and Orange Book status of CAMZYOS?

CAMZYOS is an FDA-approved prescription capsule with a REMS. The REMS requires certified prescribers and pharmacies, patient enrollment, baseline and follow-up echocardiographic monitoring, and compliance with medication-dispensing controls.[2]

The REMS affects commercial launch planning for any generic. A competing product may need:

• A comparable REMS
• A shared REMS arrangement, if accepted by FDA
• Certified pharmacy infrastructure
• Prescriber and patient support systems
• Monitoring and reporting procedures
• Inventory controls linked to echocardiographic results

The Orange Book remains the principal source for listed patents, patent use codes, and approved product information. The FDA label and Orange Book should be read together because the label defines the approved use, while the Orange Book identifies listed patent barriers.[1,3]

How strong is the CAMZYOS patent estate?

The estate is commercially meaningful because it combines a recently approved cardiovascular therapy with a low-dose oral formulation and a controlled-use distribution system. Its strength depends on claim scope and litigation outcomes, not on the number of listed patents alone.

Factors supporting patent strength

• Recently approved NCE with remaining regulatory exclusivity
• Potential compound and composition claims
• Multiple dose strengths
• Method-of-use claims directed to obstructive hypertrophic cardiomyopathy
• Clinical monitoring and dose-adjustment architecture
• REMS-linked commercial complexity

Factors creating generic opportunities

• Conventional capsule excipients
• Immediate-release dosage form
• No biologic manufacturing barrier
• Potential design-around options for formulation claims
• Established generic capsule manufacturing technology
• Ability to separate patented uses from noninfringing uses where legally available

The strongest generic strategy would likely combine a Paragraph IV challenge with a formulation design-around and a carefully structured label. The highest technical risk is not capsule manufacture. It is demonstrating bioequivalence, content uniformity, stability, and acceptable labeling while avoiding enforceable claims.

What generic launch scenarios exist for CAMZYOS?

Three scenarios are commercially relevant.

Early negotiated entry

A first filer could challenge listed patents and settle for a licensed entry date. The value of first-filer status would depend on whether other applicants also file Paragraph IV certifications and whether the settlement preserves or forfeits 180-day exclusivity.

Patent litigation through judgment

A challenger could proceed through district-court litigation. If the patent claims are invalidated or not infringed, FDA approval could follow after regulatory requirements are met. If the patents survive, entry would be delayed until expiration or a licensed date.

Post-patent multi-source entry

After the relevant patents expire, several manufacturers could enter with conventional hard capsules. Price erosion would likely be greater in this phase, while excipient suppliers would face purchasing pressure and greater emphasis on cost, dual sourcing, and manufacturing efficiency.

How does CAMZYOS compare with biologic cardiovascular products?

CAMZYOS has a lower manufacturing barrier than biologics such as monoclonal antibodies. It does not require cell culture, protein characterization, biosimilar comparability, or cold-chain biologic handling. Its competitive barriers are instead patent timing, REMS implementation, low-dose formulation control, and clinical familiarity.

Compared with conventional high-dose tablets, CAMZYOS creates greater content-uniformity risk because mavacamten is present at low strengths and is pharmacologically potent. That increases the value of excipient engineering and process validation.

What licensing opportunities exist around CAMZYOS?

The most realistic licensing opportunities are adjacent to the drug rather than centered on the basic excipients.

Potential deal areas include:

• Regional commercialization rights
• Generic or authorized-generic supply
• Capsule-shell technology
• Excipient co-processing
• Packaging and moisture-control systems
• REMS support services
• Analytical and bioequivalence services
• Manufacturing technology transfer
• Pediatric or alternate-age formulations, if clinically and regulatorily justified

Bristol Myers Squibb acquired MyoKardia, the original developer of mavacamten, for approximately $13.1 billion in 2020.[6] That transaction placed the CAMZYOS commercial program within BMS's global cardiovascular portfolio. Any licensing assessment must account for BMS's control over clinical, regulatory, manufacturing, and commercialization strategy.

Key Takeaways

• CAMZYOS uses a conventional immediate-release hard-gelatin capsule with lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.
• The primary excipient opportunity is supply assurance, not a standalone formulation patent.
• Low-dose content uniformity, powder segregation, moisture control, and capsule identification are the key technical issues.
• Specialty excipient suppliers can compete through engineered particle size, low-moisture grades, co-processed systems, and robust regulatory support.
• CAMZYOS received FDA approval in April 2022 and has approximately five years of NCE exclusivity, with the principal Paragraph IV window beginning around April 2026.
• Mavacamten is a small molecule, so generic applicants, not biosimilar developers, are the relevant competitors.
• The REMS creates a significant operational barrier for generic launch.
• Generic entry will depend on the latest enforceable Orange Book patent, litigation outcomes, FDA approval, and any settlement agreement.
• The most valuable licensing opportunities are in regional commercialization, generic supply, CDMO services, analytical support, capsule technology, and REMS infrastructure.

FAQs

Can a generic CAMZYOS use different excipients?

Yes. A generic applicant can use a different excipient system if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, dissolution, and labeling. The alternative formulation must also avoid enforceable formulation claims.

Is lactose-free CAMZYOS commercially attractive?

A lactose-free version could address a defined patient and market segment, but it would require replacement of the lactose diluent and supporting data for flow, fill weight, content uniformity, dissolution, and stability. The opportunity is technically feasible but commercially narrower than a standard generic.

Could a vegetarian capsule create a differentiated CAMZYOS product?

A hypromellose capsule could replace gelatin if the product meets performance, stability, dissolution, and regulatory requirements. The change may offer a marketing distinction, but it could also require additional comparability work and may not avoid compound or method-of-use patents.

Does the CAMZYOS REMS prevent generic competition?

No. The REMS does not permanently block generic entry. It increases the operational requirements for approval and commercialization, including pharmacy, prescriber, patient, and echocardiographic-monitoring systems.

Are CAMZYOS excipients likely to be separately patented?

The standard excipients are widely used and generally unlikely to provide standalone exclusivity. Patent value is more likely to arise from a specific co-processed excipient, particle-engineered grade, capsule composition, manufacturing process, or formulation combination.

References

1. U.S. Food and Drug Administration. (2022). CAMZYOS (mavacamten) prescribing information. Bristol Myers Squibb.

2. U.S. Food and Drug Administration. (2022). CAMZYOS REMS. FDA Risk Evaluation and Mitigation Strategies.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

5. U.S. Food and Drug Administration. (2015). Approved drug products with therapeutic equivalence evaluations. FDA.

6. Bristol Myers Squibb. (2020). Bristol Myers Squibb to acquire MyoKardia for $13.1 billion. Company announcement.